Gilead Sciences Gets Priority Voucher for Veklury
Federal Register notice: FDA has issued a priority review voucher to Gilead Sciences under the agency’s material threat medical countermeasure program. FDA determined that recently approved Veklury (remdesivir) meets the criteria for such a voucher. To view the notice, click here.